Ozempic

Chemical Namesemaglutide
Dosage FormInjection (subcutaneous; 2 mg/1.5 mL)
Drug ClassHormones
SystemEndocrine, Cardiovascular
CompanyNovo
Approval Year2017

Indication

  • To improve glycemic control in adults with type 2 diabetes mellitus.
  • To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease.
Last updated on 10/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Ozempic (semaglutide) Prescribing Information2020Novo Nordisk A/S, Denmark